---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Daratumumab - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/daratumumab
version: v1
---

# Daratumumab - NCI

# Daratumumab

Placeholder slot

(DAYR-uh-TOOM-yoo-mab)

This page contains brief information about daratumumab
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Darzalex

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4d0efe9-5e54-467e-9eb4-56fa7d53b60b&audience=consumer)

## Use in Cancer

Daratumumab
is approved to be used alone or with other drugs to treat:

- **[Multiple myeloma](/Common/PopUps/popDefinition.aspx?id=45793&version=Patient&language=English).** It is used:
- In adults with newly diagnosed disease. It is used:
- With [lenalidomide](/Common/PopUps/popDefinition.aspx?id=393761&version=Patient&language=English) and [dexamethasone](/Common/PopUps/popDefinition.aspx?id=45262&version=Patient&language=English) or with [bortezomib](/Common/PopUps/popDefinition.aspx?id=269133&version=Patient&language=English), [melphalan](/Common/PopUps/popDefinition.aspx?id=45957&version=Patient&language=English), and [prednisone](/Common/PopUps/popDefinition.aspx?id=45492&version=Patient&language=English) in patients who cannot receive an [autologous stem cell transplant](/Common/PopUps/popDefinition.aspx?id=270733&version=Patient&language=English).
- With bortezomib, [thalidomide](/Common/PopUps/popDefinition.aspx?id=45458&version=Patient&language=English), and dexamethasone in patients who can receive an autologous stem cell transplant.
- In adults with [relapsed](/Common/PopUps/popDefinition.aspx?id=45866&version=Patient&language=English) or [refractory](/Common/PopUps/popDefinition.aspx?id=45863&version=Patient&language=English) disease. It is used:
- With dexamethasone and bortezomib in patients who have received at least one therapy.
- With dexamethasone and [carfilzomib](/Common/PopUps/popDefinition.aspx?id=737706&version=Patient&language=English) in patients who have received one to three other types of therapy.
- With [pomalidomide](/Common/PopUps/popDefinition.aspx?id=589401&version=Patient&language=English) and dexamethasone in patients who have received at least two therapies that included lenalidomide and a [proteasome inhibitor](/Common/PopUps/popDefinition.aspx?id=393541&version=Patient&language=English).
- Alone in patients who have received at least three types of therapy that included a proteasome inhibitor and an [immunomodulating agent](/Common/PopUps/popDefinition.aspx?id=739791&version=Patient&language=English) or whose disease is refractory to both a proteasome inhibitor and an immunomodulatory agent.

Daratumumab is also available in a different form, combined with [hyaluronidase](/Common/PopUps/popDefinition.aspx?id=791166&version=Patient&language=English). For more information, see the Drug Information Summary for [Daratumumab and hyaluronidase-fihj](/about-cancer/treatment/drugs/daratumumabandhyaluronidase-fihj).

Daratumumab
is also being studied in the treatment of other types of
cancer.

## More About Daratumumab

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/583564) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Daratumumab](https://medlineplus.gov/druginfo/meds/a616002.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[FDA Approvals Expand Initial Treatment Options for Multiple Myeloma](https://www.cancer.gov/news-events/cancer-currents-blog/2025/fda-daratumumab-isatuximab-newly-diagnosed-myeloma)

[Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma](https://www.cancer.gov/news-events/cancer-currents-blog/2024/multiple-myeloma-darzalex-plus-vrd)

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Daratumumab](https://www.cancer.gov/research/participate/clinical-trials/intervention/C74007) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
